Wound healing in adult skin is comprised of several overlapping phases, and includes the induction of acute inflammation, the rapid proliferation of reparative cells, and the formation of a permanent scar. 1, 2 Aside from the psychological and social detriments associated with prominent scars, there are many other problems with excessive scar tissue, including restricted joint mobility, impaired growth, and loss of organ function. 3, 4 Whereas adult skin always heals with a scar, the same is not true for developing embryonic skin. Throughout the first and second trimesters of development, fetal skin heals scarlessly. 5 At this stage, skin heals by regeneration, which occurs very rapidly and without significant inflammation or scarring. 6 However, during the third trimester, the healing outcome in the skin is fibrotic, and the skin heals like that of an adult: slower, with significant inflammation, and with a scar. During development of mouse skin, the transition from scarless to fibrotic healing occurs after embryonic day 16 (E16). [7] [8] [9] Thus, murine fetal skin can be wounded in utero at E15 and E18 to investigate scarless and fibrotic fetal healing, respectively. 10 Angiogenesis, the process of new blood vessel growth, is a key element of the proliferative phase of healing. Most studies suggest that neovascularization is important for healing, supplying oxygen and nutrients to support the rapid growth of the cells mediating repair. Wound angiogenesis is controlled to a large degree by levels of the proangiogenic factor vascular endothelial growth factor-A (VEGF). 11 VEGF is a 40-to 45-kDa homodimeric glycoprotein that was initially found to regulate the permeability of blood vessels. 12 Subsequent studies also found that it was a potent mitogen for vascular endothelial cells and could induce angiogenesis in vivo. 13, 14 VEGF binds two high-affinity tyrosine kinase receptors to exert its effects on vascular endothelial cells, vascular endothelial growth factor receptor-1 (VEGFR-1) (flt-1) and VEGFR-2 (flk-1 or KDR). 15 Signaling through these receptors regulates proliferation, migration, and spread of endothelial cells required for sprouting of new vessels. 15 Keratinocytes in the epidermis are thought to be the main source of VEGF during wound healing, 16 but VEGF is also produced by dermal fibroblasts and macrophages in response to injury.
Although the majority of studies examining the function of angiogenesis in wound healing have focused on its overall effect on wound closure or reepithelialization, some suggest that angiogenesis may also impact repair in the dermis. Taken together with the fact that angiogenesis immediately precedes scar tissue formation in adult wounds, we speculated that there is a coupled regulation of these two events. To examine this linkage, fetal and adult wound healing models were used to determine the role of VEGF in the production of scar tissue.
MATERIALS AND METHODS Animal Experiments
All animal experiments were approved by the appropriate Institutional Animal Care and Use Committee prior to start of experiments.
Fetal wound healing experiments
A murine model of scarless fetal repair was used to assess the effects of VEGF on scar formation. Female and male FVB mice (Taconic, Germantown, NY, USA) were mated and surgery was performed on the pregnant female 15 or 18 days after the detection of a vaginal plug, designated as day 0. The E15 and E18 day time points represent ages at which scarless or fibrotic fetal healing take place, respectively. After preparation of the abdomen for aseptic surgery, a midline laparotomy was performed under isoflurane (Abbott Laboratories, Abbott Park, IL, USA) anesthesia. Incisions were made in the uterine wall and amniotic sac overlying each fetus, and a full-thickness incisional wound, approximately 2 mm in length, was made on the dorsum of the fetus using microsurgical scissors. A 1-ml volume of India ink (Fisher Scientific, Pittsburgh, PA, USA) diluted to 10% in sterile PBS (Invitrogen Corporation, Carlsbad, CA, USA) was injected subcutaneously into the wound site. Injection of India ink allows visualization of the area after healing has occurred. 9 To assess the effects of VEGF on scarless repair, some E15 wounds were injected with the India ink solution containing 0.1 mg recombinant murine VEGF 164 (R&D Systems, Minneapolis, MN, USA). After the wound was made and injected with ink or ink plus VEGF, the uterine incision was closed using 7-0 nylon suture. After approximately four fetuses were wounded in this manner, the muscle and skin layers of the pregnant mouse were sutured closed. One dose of xylazine (3 mg/kg; Phoenix Scientific, St Joseph, MO, USA) was given subcutaneously for sedation and analgesia. Wounds were harvested at various time points post-wounding along with age-matched unwounded skin. The tissue was frozen in TBS tissue-freezing media (Triangle Biomedical Sciences, Durham, NC, USA) for immunohistochemistry, fixed in 10% buffered formalin (Fischer Scientific, Pittsburgh, PA, USA) for histology, or snap frozen for protein analysis.
Adult wound healing experiments
Female FVB mice (8 weeks old; Taconic) were used to examine the effects of VEGF neutralization on scar formation. Four hours prior to wounding, mice received an intraperitoneal injection of 50 mg of neutralizing anti-VEGF antibodies (R&D Systems) or normal goat IgG (R&D Systems) that had been dissolved in sterile saline (Abbott Laboratories). Mice received additional injections on 2, 5, 8, and 11 days post-wounding. A similar protocol has previously been shown to inhibit angiogenesis associated with hair growth. 17 Under isoflurane (Abbott Laboratories) anesthesia, the dorsum of each mouse was shaved and wiped with 70% isopropyl alcohol. A 3-cm, full-thickness linear incisional wound was made to the right of the spine on each mouse. The wounds were closed with three stainless steel staples (Fisher Scientific). The staples were removed 5 days after the wounds were made. Mice were killed and wound or scar tissue samples were harvested 24 h or 14 days postwounding. Samples were fixed for histology or electron microscopy or frozen in TBS tissue-freezing media (Triangle Biomedical Sciences) for immunohistochemistry.
Analysis of Blood Vessel Density
Immunohistochemical staining for the endothelial cell marker PECAM-1 (CD-31) was used to identify blood vessels 10-mm cryosections of wounds or unwounded skin. Sections were thawed and fixed in acetone for 15 min. After three washes in PBS, pH 7.4, sections were treated with 0.3% H 2 O 2 in methanol for 30 min to quench endogenous peroxidase activity. The slides were washed in PBS and blocked with normal rabbit serum (1:10; Sigma Chemical Company, St Louis, MO, USA) in PBS for 30 min. Sections were incubated with 1.0 mg/ml of MEC13.3 rat anti-mouse PECAM-1 antibody (anti-CD31; BD Pharmingen, San Diego, CA, USA) in PBS. After a 30-min incubation with PECAM-1 primary antibody, the slides were washed in PBS. Sections were then incubated for 30 min with 13.3 mg/ml of mouse adsorbed biotinylated rabbit anti-rat IgG antibody (Vector Laboratories, Burlingame, CA, USA). After washes in PBS, all slides were incubated with avidin-biotin-horseradish peroxidase complex (ABC-HRP) (Vector Laboratories) for 30 min, washed, and incubated with the HRP substrate 3,3 0 -diaminobenzidine (DAB; Kirkegaard and Perry Laboratories, Gaithersburg, MD, USA) for 10 min. After counterstaining with hematoxylin-2 (Richard Allen Scientific), the sections were dehydrated in alcohols and cleared in xylene (Richard Allen Scientific), before coverslips were applied with Cytoseal 280 (Stephens Scientific, Kalamazoo, MI, USA).
PECAM-stained wound sections were used to determine the density of blood vessels within wounds or unwounded skin as outlined previously. 18 Briefly, images of stained sections were captured using Scion Image software (Scion Corporation, Frederick, MD, USA). The total dermal area to be analyzed was outlined using a freehand drawing tool and measured, and PECAM-positive area was also determined.
Using these measurements, the percentage of PECAMpositive vessels per total area analyzed (blood vessel density) was calculated.
Detection of Fibroblasts and Myofibroblasts
Immunohistochemical staining for vimentin and a-smoothmuscle actin (a-SMA) was used to identify fibroblasts and myofibroblasts, respectively. Briefly, 5-mm paraffin sections were deparaffinized and rehydrated. For vimentin staining, sections were blocked with 10% normal goat serum (Vector Laboratories) for 30 min, followed by incubation with rabbit anti-vimentin polyclonal antibody (1:200 dilution in serum) for 1 h. After washing in PBS, the sections were incubated with biotinylated goat anti-rabbit antibodies (1:200 dilution in serum; Vector Laboratories) for 30 min. For a-SMA detection, staining was performed using the mouse-onmouse (M.O.M.) kit (Vector Laboratories) as instructed by the manufacturer, with mouse monoclonal anti-a-SMA antibody (Sigma-Aldrich, St Louis, MO, USA; 30-min incubation). After washes in PBS, all slides were incubated with ABC-HRP (Vector Laboratories) for 30 min, washed, and incubated with the HRP substrate DAB (Kirkegaard and Perry Laboratories). After counterstaining with hematoxylin-2 (Richard Allen Scientific), the sections were dehydrated in varying concentrations of alcohol and cleared in xylene (Richard Allen Scientific), before coverslips were applied with Cytoseal 280 (Stephens Scientific). Scion Image software (Scion Corporation) was used to determine the density of vimentin-or a-SMA-positive staining in the sections. The total dermal area (wound bed/scar) to be analyzed was outlined using a freehand drawing tool and measured, and the percentage of positive staining per total area analyzed was determined.
Protein Isolation and ELISA Analysis
Wounds harvested 12 and 24 h, and 3, 5, and 7 days postwounding from E15 or E18 fetuses and unwounded skin were homogenized in protease inhibitor buffer (PBS containing complete protease inhibitor cocktail tablet; Roche Diagnostics, Mannheim, Germany), sonicated, and centrifuged at 10 000 r.p.m. for 10 min. Supernatants were used to analyze VEGF levels by ELISA, as directed by the manufacturer (R&D Systems). VEGF levels in picograms were normalized to total protein concentrations as determined by the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA, USA).
Measurement of Scar Width
Samples were fixed in 10% buffered formalin (Fisher Scientific), processed, and embedded in paraffin. Paraffin sections were subjected to Masson's trichrome staining as previously described. 19 The width of each scar was measured using a stage micrometer to analyze differences in scar size.
Electron Microscopy
For ultrastructural collagen analysis, normal skin and scars from mice injected with IgG or anti-VEGF antibodies were fixed in 4% glutaraldehyde. After rinsing with 0.1 mol/l sodium cacodylate buffer, samples were post-fixed in 1% osmium tetroxide, dehydrated in graded alcohols, and embedded in Spurr's epoxy resin (Electron Microscopy Sciences, Fort Washington, PA, USA). Ultrathin sections (80 nm) were collected on grids, stained with uracyl acetate and lead citrate, and examined using a Hitachi H-600 (75 kv) transmission electron microscope (TEM). TEM images of collagen fibril cross-sections were taken at a magnification of Â 30 000 and the photographic negatives were scanned into Adobe Photoshop (Adobe Systems Incorporated, San Jose, CA, USA). Fibril diameters were measured using Scion Image (Scion Corporation) and histograms were produced using GraphPad Prism (GraphPad Software Inc., San Diego, CA, USA). Collagen fibril diameter measurements have been used previously to evaluate the degree of cutaneous fibrosis. [20] [21] [22] Three normal skin samples and six scar samples from each treatment group, all from different mice, were used for analysis. Each micrograph was divided into four parts for analysis and fibrils from four micrographs per sample were measured. A total of 4800-8000 fibrils per group were analyzed.
Analysis of Inflammation
Immunohistochemical staining for neutrophils (Ly-6G) and macrophages (MOMA-2) was performed as described above for PECAM, with the following modifications: Ly-6G conditions (primary rat anti-mouse Ly-6G antibody, 1:100 dilution; BD Pharmingen), MOMA-2 conditions (primary anti-MOMA-2 antibody, 1:200 dilution; Serotec, Raleigh, NC, USA), and secondary antibody conditions for both primary antibodies (mouse adsorbed biotinylated rabbit antirat IgG antibody, 1:50; Vector Laboratories). All antibody incubations were performed for 30 min at room temperature. Wound sections stained for Ly-6G or MOMA-2 were used to determine the number of neutrophils or macrophages in tissue immediately adjacent to the wound margins. The measurements were made in 100 Â fields.
Statistical Analysis
Data were analyzed using GraphPad Prism (GraphPad Software Inc.). Statistical differences were determined by two-way ANOVA with Bonferroni post tests or unpaired t-tests, with values of Po0.05 considered statistically significant.
RESULTS

Increased Blood Vessel Density and VEGF Levels Coincide with Scarring in Fetal Wounds
Fetal skin can heal with or without a scar, depending on the developmental age of the fetus. We determined whether differences in angiogenesis occur during the transition from scarless (E15) to fibrotic (E18) healing in fetal skin. When fetuses were wounded at E15, blood vessel density was similar in wounded skin 7 days post-wounding (Figure 1a and c) and age-matched, unwounded skin (control). However, when fetuses were wounded at E18, the wounds exhibited nearly a twofold increase in vessel density compared with control skin (Figure 1b and c) . The increased vascular density in scarforming E18 wounds suggests a link between the levels of wound angiogenesis and the amount of scar tissue formed as a result of the healing process.
Protein levels of the proangiogenic molecule VEGF were assessed by ELISA in wounds made at E15 or E18, or in unwounded skin (Figure 1d ). VEGF levels in wounds generated at E15 remained at steady, low levels over the time course of healing. In contrast, wounds generated at E18 contained significantly higher levels of VEGF than those generated at E15. In wounds generated at E18, VEGF levels peaked at 3 days post-wounding with fourfold higher levels than in E15 wounds (8.06±0.94 vs 1.99±0.18 pg/mg total protein), and then gradually decreased and returned to baseline by day 7. Taken together, it is likely that the increase in vascular density during healing of E18 skin results from production of more VEGF during repair at the fibrotic healing stage.
VEGF Promotes Angiogenesis and Scar Formation in Early Fetal Skin
The production of high levels of VEGF in fibrotic (E18) fetal wounds ( Figure 1 ) suggested that VEGF was playing a novel role in the production of scar tissue. To investigate this possibility, the effect of exogenous VEGF on scarless fetal wound healing was examined. Wounds were made at E15 and either injected with PBS as a control or with 0.1 mg of rmVEGF 164 and harvested 10 days post-wounding. Analysis of blood vessel density within the wounds demonstrated the ability of this dose of VEGF to increase the level of angiogenesis, as there was a significantly higher density of blood Figure 1 Blood vessel density and VEGF protein production in scarless and fibrotic fetal wounds. Immunohistochemical staining for PECAM was used to identify blood vessels in scarless (a, E15) and fibrotic (b, E18) fetal wounds 7 days post-wounding. Arrows indicate the wound bed or scar margins (scale bar ¼ 100 mm). Blood vessel densities were calculated and are represented graphically (c). Data from day 7 wounds and unwounded, age-matched skin (control) are shown. The bars and lines represent means ± s.e.m.; *Po0.0076, unpaired t-test; n ¼ 3 per age for control skin; n ¼ 10 for E15 wounds, and n ¼ 7 for E18 wounds. VEGF protein levels in unwounded skin and wound homogenates were measured by ELISA (d). VEGF levels in wounds made at E15 (') or E18 (K) were measured during healing. Unwounded E15 (&) and E18 (J) skin are also shown. The amount of VEGF (pg) was normalized to total protein content (mg). Points and lines on the graph represent means ± s.e.m.; **Po0.001 and *Po0.05, two-way ANOVA and Bonferroni posttests; n ¼ 3-6 per time point. vessels in wounds injected with VEGF (Figure 2b and c) compared with control wounds (Figure 2a and c) .
Wound sections were also subjected to Masson's trichrome staining and examined for presence of scar tissue. As expected, control wounds injected with PBS (Figure 3a and b) healed without a scar. In contrast, wounds injected with rmVEGF 164 healed with an obvious scar (Figure 3c and d) indicated by loss of hair follicles and densely packed, disorganized collagen. The intensity of the trichrome stain demonstrates increased collagen content in VEGF-injected wounds. The ability of VEGF to promote scar tissue in wounds that would otherwise heal scarlessly further supports a link between VEGF, angiogenesis, and scarring.
Identification of Fibroblasts and Myofibroblasts in Fetal Wounds
The potential mechanisms for VEGF-induced scar formation in fetal wounds include an increase in fibroblast numbers or an increased presence of myofibroblasts, a cell type known to correlate with scarring in fetal wounds. Immunohistochemical staining was used to identify vimentin-positive fibroblasts and a-SMA-positive myofibroblasts in E15 wounds injected with either PBS or rmVEGF 164 at 7 days post-wounding, and image analysis was used to determine the density of the staining. As shown in Figure 4 , an increased number of vimentin-positive cells were seen in VEGF-treated wounds (Figure 4b ) compared to control wounds injected with PBS (Figure 4a ). Interestingly, in addition to an increase in overall vimentin-positive staining, a different pattern of expression was also noted, with vimentin staining present in the more superficial areas of the dermis in control wounds compared with staining in the deeper dermis in VEGFtreated wounds. There was also more intense staining for a-SMA in VEGF-treated wounds (Figure 4e ) compared to controls (Figure 4d ). Significant increases in the percentage of vimentin- (Figure 4c ) and a-SMA-positive staining (Figure 4f ) within the wound bed/scar following VEGF injection were confirmed using image analysis. Taken together, these data suggest that an increase in total fibroblast numbers and/or an increase in myofibroblast numbers could be responsible for scar tissue production after exposure to VEGF.
Effects of VEGF Neutralization on Wound Vascularization and Scar Formation in Adult Skin
To further explore the role of VEGF in dermal scarring, neutralizing VEGF antibodies were used to block VEGF activity in an adult murine incisional wound model. Before determining any effects of anti-VEGF antibody injections on the repair process, the effectiveness of the treatment regimen was verified. Injections with anti-VEGF antibodies (Figure 5b ) significantly reduced the density of PECAMpositive blood vessels within the wound area 14 days post injury ( Figure 5c ) compared with wounds from mice injected with goat IgG antibodies (Figure 5a ), confirming the ability of anti-VEGF antibodies to neutralize VEGF.
The effect of anti-VEGF antibody injections on scarring was assessed by measuring the width of the scars in Masson's trichrome-stained tissue sections. Histologically, scars from mice injected with anti-VEGF antibodies (Figure 6b and c) were significantly smaller in width than those from control mice injected with IgG (Figure 6a and c) . Injections with anti-VEGF antibodies resulted in nearly a 75% reduction in scar width, with an average width of 48 ± 6 mm, compared with control scars, which were 197 ± 59 mm in width.
VEGF Blockade Influences the Organization of Scar Tissue
In addition to the size of the scars (Figure 6 ), ultrastructural collagen organization was examined as an indication of the quality of the scar tissue. Using TEM, the diameter of the collagen fibrils was determined in normal unwounded skin (Figure 7a ) as well as scar tissue from mice injected with IgG control (Figure 7b ) and anti-VEGF (Figure 7c) antibodies. The relative frequencies within a specific range of diameters were calculated and a histogram to show the differences in the distribution of collagen fibril diameters was created (Figure 7d ). As expected, unwounded skin contained relatively large collagen fibrils of a uniform size, most in the range of 41 to 80 nm. In contrast, scar tissue from control mice injected with IgG antibodies contained a high frequency of very small-diameter fibrils (less than 40 nm), similar to what is found in models of cutaneous fibrosis. [20] [21] [22] Scars from mice injected with anti-VEGF antibodies contained a lower frequency of the small-diameter fibrils (0-40 nm) and a higher frequency of fibrils within the normal range (41-80 nm) compared with control scars. The results suggest that neutralization of VEGF not only reduced the amount of scar tissue formed (Figure 6 ), but also improved the quality of the scar tissue that did form by shifting the collagen fibril distribution to a state more closely resembling normal skin (Figure 7) .
Neutralization of VEGF does not Alter Acute Wound Inflammation
Inflammation is known to play a crucial role in regulating scar tissue formation in both fetal and adult wounds. Therefore, we investigated whether the effects of VEGF blockade on scarring could be attributed to a decrease in acute inflammation with anti-VEGF antibody injections. Immunohistochemistry was used to detect neutrophils (Figure 8a ) or macrophages ( Figure 8b ) in 24 h wounds, and the number of cells per high-power field (HPF) was counted. As shown in Figure 7 , there were no significant differences in acute wound neutrophil or macrophage numbers between the treatment groups. 
DISCUSSION
Angiogenesis is a major component of wound repair, and in adult skin results in a peak vascular density 2-3 times that in normal skin. 18 Angiogenesis is thought to facilitate the delivery of oxygen and nutrients to the wound site for use by rapidly proliferating reparative cells. It is not surprising then, that many studies have found angiogenesis to be beneficial for wound repair. Stimulation of angiogenesis can enhance healing rates, [27] [28] [29] [30] [31] [32] [33] whereas a reduction in angiogenesis can impair the same. [34] [35] [36] [37] The benefits of enhanced angiogenesis have primarily been shown in models of impaired wound healing 28, 32, 33 or severe injury. [29] [30] [31] In contrast, several reports have shown that modulation of angiogenesis does not affect epidermal healing rates or overall wound closure to a great degree, [38] [39] [40] [41] [42] [43] and some studies have even reported enhanced healing with reduced angiogenesis. 44 Thus, although there are many studies examining angiogenesis and wound repair, the degree to which angiogenesis actually facilitates healing under normal circumstances is still not known.
The effects of angiogenesis on the repair of the dermis, in particular, have been poorly studied; therefore, it is not known how angiogenesis specifically impacts collagen production and remodeling during wound repair. Our data demonstrating distinct patterns of angiogenesis and VEGF production between scarless and fibrotic fetal wounds, the ability of VEGF to promote scar tissue deposition in scarless wounds, and reduction of scar formation when VEGF is neutralized in adult wounds, suggest that VEGF-mediated angiogenesis plays a significant role in scar formation.
The idea that angiogenesis may affect scar formation is not entirely without precedence, as there have been a few studies suggesting that angiogenesis inhibitors can modify dermal matrix deposition. For example, endostatin treatment during wound healing has been described to alter collagen deposition, 45 and CM101 has been suggested to reduce scarring in Kaposi's sarcoma patients. 46 ZD6474, an inhibitor of VEGFR-2 receptor tyrosine kinase activity, has recently been reported to reduce the degree of fibrosis after wound healing. 47 In fetal wounds, most studies have suggested that there are reduced levels of angiogenesis in scarless fetal wounds. 48, 49 In addition, fetal studies have shown that factors capable of inducing angiogenesis, such as transforming growth factor-b (TGF-b), 50 platelet-derived growth factor, 51 basic fibroblast growth factor, 52 interleukin-8, 53 and prostaglandin E 2 , 54 are either present at lower levels during scarless healing or can induce scarring when added to these wounds. 10, 48, [55] [56] [57] In line with these previous reports, our studies indicate that scarless fetal wounds heal without a robust increase in vascularity or VEGF levels, in contrast to fibrotic fetal wounds. Although several studies have suggested lower levels of angiogenesis in scarless fetal wounds, one recent study reported increased VEGF mRNA levels and angiogenesis in scarless compared to fibrotic fetal wounds. 58 In this study, a rat model of excisional fetal wound healing was used, VEGF mRNA was assessed, blood vessels were not identified immunohistochemically, and early time points were examined. In the studies presented here, a mouse model of incisional fetal wound healing was used, VEGF protein levels were assessed, PECAM-positive vessels were analyzed, and a wider range of time points were examined. It is likely that differences in the model systems, methods, and time points examined account for the variability in results between these two studies.
Our results, using three independent systems, show that VEGF levels influence the amount of scar tissue that will be produced during the wound repair process. There are several possible mechanisms by which VEGF could promote scar tissue deposition. Inflammation is known to influence the amount of scar tissue that will be generated during the repair process. This has been shown both in fetal and adult wound-healing systems. 10, 19, 25, 26, 57, [59] [60] [61] [62] Due to the ability of VEGF to promote inflammatory cell recruitment 63, 64 and vascular permeability, 12 it seemed possible that the reduction in scar formation seen after treatment with anti-VEGF antibodies might, therefore, be a result of reduced inflammation. However, we saw no differences in acute inflammation with anti-VEGF antibody treatment, suggesting that the reduction in scarring is not completely a result of reduced inflammation.
Second, VEGF could encourage scar tissue deposition indirectly by virtue of its effects on angiogenesis, if the process of angiogenesis itself promotes scar tissue production. For example, it is possible that while undergoing angiogenesis, dermal endothelial cells could generate significant amounts of TGF-b, connective tissue growth factor, or other profibrotic factors, stimulating subsequent scar tissue production by neighboring fibroblasts. Alternatively, the matrix remodeling that accompanies angiogenesis could indirectly stimulate the production of scar tissue.
Finally, it is possible that VEGF itself could be acting as the link between angiogenesis and scar formation, by directly stimulating both endothelial cells and dermal fibroblasts. Our fetal wound healing studies showed an increase in both total fibroblast numbers as well as a-SMA-positive myofibroblasts in VEGF-treated wounds that formed scars, suggesting VEGF may affect fibroblasts. Wu et al 65 recently demonstrated the ability of VEGF to induce proliferation of keloid fibroblasts and suggest the presence of functional VEGF receptors on fibroblasts. The presence of VEGF receptors on fibroblasts is also supported by a study demonstrating expression of VEGFR-2 in stromal cells during wound repair in vivo.
66
Unpublished data from our laboratory also indicate VEGFR expression in dermal fibroblasts, and studies are underway to confirm the presence of functional VEGF receptors on dermal fibroblasts and to determine whether VEGF can influence scar formation directly via signaling in fibroblasts.
Together, our results strengthen the link between angiogenesis and scarring, and suggest a novel role for VEGF in mediating the quantity and quality of scar tissue generated during wound repair. Our results are supported by reports indicating that increased VEGF levels are important for development of fibrosis in other models, including bleomycininduced lung fibrosis 67 as well as liver fibrosis. 68, 69 High levels of VEGF have also been described in keloids in the skin. 70, 71 Further studies will have to be conducted to assess potential clinical uses for VEGF neutralization in limiting scar formation or managing more severe fibrotic diseases.
